- Details
- (Length of Discussion: 16 min) Charles Ryan and Badrinath Konety discuss the challenges and promises you see as a chair of a department of urology at a major academic medical center in the US. Topics discussed are avoiding burnout and the quality of life in academia. Specific programs and strategies incorporated at the University of Minnesota including fostering the growth of young science focused...
|
- Details
- (Length of Conversation: 9 min) Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL). This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and re...
|
- Details
- (Length of Conversation: 16 min) Matthew Cooperberg and Charles Ryan discuss active surveillance in the low risk and low volume disease setting. The topics they highlight include defining the appropriate patient for active surveillance in 2018 and reaching a global consensus, how much age factors into active surveillance, how biomarkers and imaging are driving research and decision making in the a...
|
- Details
- (Length of Discussion: 11 min) Silke Gillessen, in conversation with Alicia Morgans provides an overview of many of the changes taking place in prostate cancer clinical practice since the 2017 APCCC. They touch upon the new data that is driving change in clinical practice and some unanswered questions that have arisen and will be discussed in the upcoming 2019 Advanced Prostate Cancer Consensus Co...
|
- Details
- (Length of Conversation: 7 min) Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD,...
|
- Details
- (Length of Interview: 15 min) Badrinath Konety and Alicia Morgans discuss biomarkers in bladder cancer. Concepts highlighted include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. Biographies: Badrinath Konety, MD, MBA , is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-On...
|
- Details
- Karim Fizazi and Alicia Morgans discuss various treatment data in the metastatic hormone-sensitive space, including the LATITUDE, CHAARTED and STAMPEDE trials. The European Consortium Prostate Cancer Consortium in Europe (PEACE) trials were designed for the current generation of prostate and advanced prostate cancer patients and was established in 2013 to facilitate large academic clinical trials...
|
- Details
- (Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...
|
- Details
- (Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...
|
- Details
- (Length of conversation: 11 min) Cora Sternberg, MD and Alicia Morgans, MD explore the importance of the study results from Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) . The purpose of this study was to assess the safety and efficacy of enzalutamide in patients with non metastatic (M0) prostate cancer. Dr. Sternberg discus...
|
